A new systematic review is putting a closely watched question in the spotlight: whether taking antidepressants during pregnancy or after childbirth is associated with changes in breastfeeding behavior. The review, published in the Journal of Perinatology by Desaunay, Blouet, Alexandre and colleagues, examines an issue at the intersection of perinatal mental health, infant nutrition and maternal decision-making. Its focus is not simply whether mothers breastfeed, but whether antidepressant exposure is linked to when breastfeeding begins, how long it continues, whether exclusive breastfeeding is maintained and why feeding practices may change during the demanding transition into parenthood.
The question matters because depression and anxiety are common during pregnancy and the postpartum period, while breastfeeding is widely promoted for its potential benefits to infants and mothers. These two realities can collide in clinical conversations. A parent may need effective treatment for depression while also worrying that medication could affect milk production, infant exposure or the practical experience of feeding. At the same time, breastfeeding itself can be influenced by sleep deprivation, pain, delivery complications, social support, economic pressure, previous experience and the severity of mental illness. Separating the possible influence of antidepressants from these overlapping factors is therefore one of the central scientific challenges.
Antidepressants are prescribed to help regulate brain signaling pathways involved in mood, stress responses and emotional processing. The most frequently used medicines in pregnancy and postpartum care include selective serotonin reuptake inhibitors, or SSRIs, which increase the availability of serotonin at synapses by limiting its reabsorption by nerve cells. Other classes, including serotonin–norepinephrine reuptake inhibitors and older antidepressants, may also be used depending on a patient’s history and symptoms. Although only small amounts of many medicines may pass into breast milk, exposure depends on the specific drug, dose, timing, metabolism and the infant’s age and health. These pharmacological details make it difficult to treat “antidepressant exposure” as a single, uniform condition.
The review addresses another layer of complexity: breastfeeding behavior is not a single biological outcome. It is a sequence of decisions and experiences that may begin before birth and evolve over weeks or months. Researchers may distinguish initiation from continuation, partial from exclusive breastfeeding, and intended feeding plans from actual feeding practices. A mother may begin breastfeeding but stop earlier than planned, combine breast milk with formula, temporarily interrupt feeding or decide not to initiate at all. Each pattern can reflect different influences, and collapsing them into one category could hide meaningful associations between medication use and feeding outcomes.
The timing of exposure is especially important. Antidepressant use during pregnancy may indicate that a person entered the postpartum period with a history of depression, anxiety or another psychiatric condition. That underlying condition may itself affect motivation, energy, confidence, sleep and the ability to maintain a demanding feeding routine. Exposure after delivery may reflect symptoms that emerged or intensified postpartum, a period when lactation is being established and daily care is unusually intense. A review that compares these time windows can help researchers ask whether breastfeeding outcomes are related primarily to the medication, the illness being treated, or the broader circumstances surrounding both.
This distinction is known as confounding, a major issue in observational medical research. In a randomized trial, participants would ideally be assigned to treatment or no treatment, but such designs are often ethically and practically difficult during pregnancy and breastfeeding. Instead, researchers commonly analyze medical records, surveys or cohort data in which medication decisions have already been made. People taking antidepressants may differ from those who are not taking them in ways that also influence breastfeeding, including mental-health history, age, education, income, smoking, obstetric complications, partner support and access to lactation care. A systematic review can compare how individual studies handled these variables and whether apparently similar findings remain consistent after adjustment.
The review is therefore relevant to a broader scientific debate about how medication safety is communicated. Fear of harming an infant can lead some patients to stop treatment suddenly, while untreated or undertreated depression can also carry serious consequences for the parent–infant relationship, daily functioning and family wellbeing. The presence of an association between antidepressant exposure and a breastfeeding outcome, if observed in a study, would not automatically prove that the medication caused the behavior. Nor would an absence of association guarantee that every drug has the same effect for every family. The clinical meaning depends on the strength of the evidence, the particular medicine, dosage, timing and the alternatives available to the patient.
Biology could plausibly connect mental health treatment with breastfeeding in several ways, but these pathways remain difficult to disentangle. Depression can alter appetite, sleep, motivation and stress physiology, all of which may influence lactation and feeding routines. Some antidepressants affect serotonin and other signaling systems that are also involved in mammary-gland function, although the relationship between these pathways and real-world milk production is not straightforward. Medication-related side effects such as nausea, fatigue or sleep changes could affect feeding indirectly, while improvement in mood could make it easier for a parent to initiate or continue breastfeeding. In other words, treatment might theoretically be associated with both challenges and benefits, depending on the person and the circumstances.
By bringing available studies together, the systematic review can show where the evidence is most reliable and where major gaps remain. It may also reveal whether studies use comparable definitions, whether they distinguish drug classes and whether they follow families long enough to capture changes over time. Such comparisons are essential because small studies may produce conflicting results simply through differences in recruitment, measurement or sample composition. The review’s central contribution is to place breastfeeding behavior within the full context of perinatal antidepressant use rather than treating medication exposure as an isolated variable.
For families and clinicians, the message is likely to be less about a universal yes-or-no answer and more about individualized risk assessment. Decisions about continuing, changing or beginning antidepressant treatment during pregnancy or breastfeeding should account for the severity of symptoms, previous treatment response, the specific medicine, infant health and the parent’s feeding goals. Abruptly stopping medication without medical guidance can create its own risks. The emerging evidence summarized in this review highlights why perinatal mental-health care works best when psychiatric support, obstetric care, pediatric monitoring and lactation guidance are coordinated. Understanding how antidepressant exposure relates to breastfeeding behavior is not only a question of drug safety; it is a window into the complex biological, psychological and social forces shaping the first months of family life.
Subject of Research: The association between antidepressant exposure during pregnancy or the postpartum period and breastfeeding behaviors.
Article Title: Antidepressants and breastfeeding behaviors: a systematic review
Article References: Desaunay, P., Blouet, C., Alexandre, M. et al. Antidepressants and breastfeeding behaviors: a systematic review. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02867-8
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41372-026-02867-8
Keywords: Antidepressants, breastfeeding, pregnancy, postpartum, perinatal mental health, lactation, infant feeding, systematic review
Tags: barriers to exclusive breastfeeding with antidepressantsBreastfeeding and antidepressant use during pregnancyclinical considerations for breastfeeding mothers on medicationeffects of depression on breastfeeding durationimpact of medication on infant feedinginfant nutrition and maternal medication exposureinfluence of antidepressants on milk productionmaternal decision-making in breastfeedingmental health treatment during pregnancypostpartum anxiety and feeding practicesPostpartum Mental Healthsystematic review of perinatal antidepressant use
